SSY Group Shares Surge Over 5% Intraday Following 13% Rise in First-Half Net Profit

Deep News08-26

SSY GROUP (02005) saw its share price climb more than 5% during the afternoon trading session, before settling to a gain of 3.78% at HK$2.61 per share, with turnover reaching HK$24.29 million.

The company released its 2026 interim results at midday, reporting revenue of HK$2.361 billion for the first half, a year-on-year increase of 9.94%. Profit attributable to equity holders of the company reached HK$320 million, up 12.99% compared to the same period last year, with basic earnings per share of HK$0.1107. An interim dividend of HK$0.055 per share has been proposed.

Breaking down the business segments, the infusion products division achieved counter-trend growth in both production and sales volumes during the period, with sales volume reaching 868 million bottles (bags), representing a 21.4% increase. Revenue from this segment totaled HK$1.487 billion, a 24.0% year-on-year improvement. The small-volume injection business recorded sales of HK$163 million, up 3.5%, while oral formulations saw sales of HK$165 million, a 44% decline. The active pharmaceutical ingredient segment generated sales of HK$395 million, marking a 9.4% increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129887868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129887868","market":"sg","top_or_hot":-1,"title":"SSY Group Shares Surge Over 5% Intraday Following 13% Rise in First-Half Net Profit","media":"Deep News","content":"<p><b>SSY GROUP</b> (02005) saw its share price climb more than 5% during the afternoon trading session, before settling to a gain of 3.78% at HK$2.61 per share, with turnover reaching HK$24.29 million.<br><br>The company released its 2026 interim results at midday, reporting revenue of HK$2.361 billion for the first half, a year-on-year increase of 9.94%. Profit attributable to equity holders of the company reached HK$320 million, up 12.99% compared to the same period last year, with basic earnings per share of HK$0.1107. An interim dividend of HK$0.055 per share has been proposed.<br><br>Breaking down the business segments, the infusion products division achieved counter-trend growth in both production and sales volumes during the period, with sales volume reaching 868 million bottles (bags), representing a 21.4% increase. Revenue from this segment totaled HK$1.487 billion, a 24.0% year-on-year improvement. The small-volume injection business recorded sales of HK$163 million, up 3.5%, while oral formulations saw sales of HK$165 million, a 44% decline. The active pharmaceutical ingredient segment generated sales of HK$395 million, marking a 9.4% increase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group Shares Surge Over 5% Intraday Following 13% Rise in First-Half Net Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group Shares Surge Over 5% Intraday Following 13% Rise in First-Half Net Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-26 14:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>SSY GROUP</b> (02005) saw its share price climb more than 5% during the afternoon trading session, before settling to a gain of 3.78% at HK$2.61 per share, with turnover reaching HK$24.29 million.<br><br>The company released its 2026 interim results at midday, reporting revenue of HK$2.361 billion for the first half, a year-on-year increase of 9.94%. Profit attributable to equity holders of the company reached HK$320 million, up 12.99% compared to the same period last year, with basic earnings per share of HK$0.1107. An interim dividend of HK$0.055 per share has been proposed.<br><br>Breaking down the business segments, the infusion products division achieved counter-trend growth in both production and sales volumes during the period, with sales volume reaching 868 million bottles (bags), representing a 21.4% increase. Revenue from this segment totaled HK$1.487 billion, a 24.0% year-on-year improvement. The small-volume injection business recorded sales of HK$163 million, up 3.5%, while oral formulations saw sales of HK$165 million, a 44% decline. The active pharmaceutical ingredient segment generated sales of HK$395 million, marking a 9.4% increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"","article_id":"1129887868","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129887868","pubTimestamp":1787724632,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"SSY GROUP (02005) saw its share price climb more than 5% during the afternoon trading session, before settling to a gain of 3.78% at HK$2.61 per share, with turnover reaching HK$24.29 million.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02005":"石四药集团","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","BK1191":"制药"},"translate_title":"上半年净利润增长 13%，SSY 集团股价盘中飙升超过 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY GROUP (02005) saw its share price climb more than 5% during the afternoon trading session, before settling to a gain of 3.78% at HK$2.61 per share, with turnover reaching HK$24.29 million.The company released its 2026 interim results at midday, reporting revenue of HK$2.361 billion for the first half, a year-on-year increase of 9.94%. Profit attributable to equity holders of the company reached HK$320 million, up 12.99% compared to the same period last year, with basic earnings per share of HK$0.1107. An interim dividend of HK$0.055 per share has been proposed.Breaking down the business segments, the infusion products division achieved counter-trend growth in both production and sales volumes during the period, with sales volume reaching 868 million bottles (bags), representing a 21.4% increase. Revenue from this segment totaled HK$1.487 billion, a 24.0% year-on-year improvement. The small-volume injection business recorded sales of HK$163 million, up 3.5%, while oral formulations saw sales of HK$165 million, a 44% decline. The active pharmaceutical ingredient segment generated sales of HK$395 million, marking a 9.4% increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129887868","isCrawlerRequest":true}